RT PCR report was suggestive of COVID POSITIVE in 17 patients (11.72%). Symptoms were chest pain

(80%), breathlessness (44.14%), sweating (39.31%) and palpitation (34.48%). 66 patients presented with a classical symptom triad of MI (chest pain, breathlessness, sweating). Majority of patients were seen at 4- 8 hours from onset of symptoms (29.66%), followed by at 1- 4 hours from onset of symptoms (20.69%). LVEF > 35% was noted in 53.79% patients. In the present study, Anterior Wall MI (61.38%), Inferior Wall MI (22.07%) and Inferior posterior MI (8.97%) were noted. We thrombolysed 103 patients (71.03%). Majority with streptokinase (43.45%) followed by Tenecteplase (24.83%) and Reteplase (2.76%). 35 patients were thrombolysed within 30 minutes. Door to needle time was less than 1 hour in 63.45% patients. Primary PTCA was done in 7 patients. Door to balloon time was < 1 hour and 1-2 hours in 42.85% patients. We used GPIIbIIIa inhibitors in 34.48% patients. (tirofiban- 33.10% and eptifibatide- 1.38%). In present study PTCA was DONE in 101 patients (69.66%). Common findings were single vessel PTCA (34.48%), Multivessel (26.90%), LAD (18.62%), RCA (8.97%), LCX (5.52%). In the present study, common complications noted were heart failure (34.48%), cardiogenic shock (21.38%), malignant arrhythmias (VT, VF) (15.17%) and MR (3.45). 4 deaths were noted during hospital stay. Majority of patients were discharged in 2-4 days(71.72%). 

Conclusion: In COVID pandemic, STEMI patients had longer total ischemic time, leading to a more severe disease status on hospital admission, as well as a higher rate of in-hospital adverse events was noted.